The transition from an early-stage pipeline to late-stage clinical execution fundamentally changes the problems a biotechnology company has to solve. For Slate Medicines, a Raleigh, North Carolina-based clinical-stage company developing treatments for migraine and other headache disorders, that shift is currently underway. As the company advances its lead candidate, SLTE-1009—an anti-PACAP/VIP monoclonal antibody designed for infrequent subcutaneous administration—it is bringing in heavy-hitting expertise to guide the path forward. Slate has appointed Stephen K. Brannan, MD, and John D. Young to its board of directors, adding decades of specialized experience in central nervous system drug development and global pharmaceutical commercialization.
The dual appointments signal a clear strategic priority for Slate: aligning clinical trial execution with the corporate strategy required to eventually bring a novel neurological therapy to a crowded, high-demand market. The migraine space is highly competitive, dominated by established classes of preventive treatments. SLTE-1009 aims to offer an alternative for patients inadequately served by current therapies, a goal that requires both rigorous evidence generation and savvy portfolio decision-making to secure clinical adoption.
“Stephen has helped bring multiple CNS treatments from the clinic to approval, while John has shaped corporate strategy, partnerships and portfolio decisions at a leading global pharmaceutical company,” noted Gregory Oakes, CEO of Slate Medicines, pointing to the specific leverage each new member provides as the company scales its operations. Oakes emphasized that their combined experience will support not just SLTE-1009, but the company’s broader pipeline ambitions.
About Stephen Brannan
For a clinical-stage company targeting complex neurological pathways, the regulatory and clinical hurdles are steep. Stephen Brannan joins the board with a track record of clearing them. His appointment brings more than 25 years of experience in clinical development specifically tailored to central nervous system disorders, offering Slate critical oversight as it evaluates the efficacy, safety, and dosing characteristics of SLTE-1009.
Brannan most recently served as Chief Medical Officer at Karuna Therapeutics from 2017 to 2024. During his tenure, he oversaw the clinical development of KarXT, a combination of xanomeline and trospium, guiding it through Phase 3 studies in schizophrenia. That program ultimately resulted in the approval of Cobenfy—a massive validation moment in the CNS space and one of the most closely watched psychiatric drug approvals in decades. Advancing neurological treatments requires precisely coordinated clinical trial execution, robust regulatory planning, and evidence generation that stands up to intense scrutiny. Brannan’s recent success at Karuna provides a blueprint for navigating those late-stage complexities.
Before his pivotal run at Karuna, Brannan built a formidable resume across the pharmaceutical industry, holding clinical and medical leadership positions at Forum Pharmaceuticals, Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly. At Takeda, he notably served as Therapeutic Area Head for CNS, managing broad portfolios and making the critical go/no-go decisions that define a pipeline’s viability. This extensive background in managing late-stage CNS development programs directly aligns with Slate’s clinical strategy as it pushes deeper into human trials.
“Migraine remains a disease where many people are still looking for better options,” Brannan noted, framing SLTE-1009 as a potentially differentiated preventive treatment.
He plans to apply lessons from his extensive CNS drug development background to support the program’s progress. A board-certified psychiatrist, Brannan anchors his extensive industry experience in a strong academic foundation, holding an undergraduate degree from Harvard University and a medical degree from the University of Texas Southwestern Medical School.
About John Young
If Brannan represents the clinical execution engine, John Young brings the commercial and strategic architecture. Young joins Slate’s board to provide oversight on the operational and financial considerations involved in developing and bringing pharmaceutical products to a global market—a perspective forged during a 35-year career at one of the world’s largest and most complex drugmakers.
Young retired from Pfizer in 2022, having most recently served as Group President and Chief Business Officer while sitting on the company’s Executive Leadership Team. In that capacity, his responsibilities spanned corporate strategy, business development, portfolio decisions, and commercialization. He understands what makes an asset valuable not just in the clinic, but in the marketplace, and how to structure the partnerships, scale the manufacturing, and execute the corporate maneuvers required to maximize that value. For a clinical-stage biotech looking down the barrel of late-stage trials and potential commercialization, having a former Pfizer executive in the boardroom provides an invaluable strategic backstop.
“Slate has developed a compelling portfolio of assets that has the potential to impact the lives of migraine patients globally,” Young shared, signaling his focus on the broader commercial and strategic horizon for the company’s development programs.
His post-Pfizer board experience underscores his ongoing influence in the life sciences sector. Young currently serves on the boards of Novartis AG and Johnson Controls International, bringing high-level governance and multinational operational expertise to Slate’s boardroom. He holds a bachelor’s degree in biological sciences from the University of Glasgow and an MBA from Strathclyde Graduate Business School.
About Slate Medicines
Based in Raleigh, North Carolina, Slate Medicines is a clinical-stage biotechnology company focused on addressing the persistent unmet needs in migraine and related headache disorders. The company’s pipeline is built around targeting specific signaling pathways to offer differentiated therapeutic options for patients requiring long-term prevention.
Slate’s lead investigational candidate, SLTE-1009, utilizes a monoclonal antibody approach targeting both the PACAP and VIP signaling pathways. A key differentiator for the program is its design for subcutaneous administration with less frequent dosing—a critical consideration for patient adherence and clinical adoption in the chronic migraine space, where treatment effectiveness, tolerability, and administration schedules heavily influence physician prescribing behavior.
As the company advances its broader portfolio, it remains focused on the intersection of clinical viability and patient convenience. By integrating clinical development rigor with high-level pharmaceutical business leadership, Slate is positioning itself to navigate the complex strategic and commercial decisions that accompany later-stage drug programs. These recent appointments, detailed further in the company’s official announcement, underscore a deliberate effort to strengthen board oversight across two critical priorities: advancing investigational therapies through clinical development, and preparing for the market realities of commercialization.
